Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.42 |
| ▸ | TDO2 | P48775 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27723763 | 0.83 | NPC1 (0.42) | CYP11B1CYP11B2CYP1A2NPY5RCYP2A6 | |
| SCHEMBL5583665 | 0.80 | CYP11B1 (0.47) | CYP17A1TDO2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL27723761 | 0.77 | PTGS2 (0.35) | TDO2CYP11B2CYP3A4ALDH1A1GPR84 | |
| SCHEMBL4597056 | 0.75 | TDO2 (0.38) | CYP17A1TDO2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL4597059 | 0.75 | PARP1 (0.47) | CYP17A1TDO2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL27723664 | 0.74 | AQP1 (0.36) | GPR84 | |
| SCHEMBL27723675 | 0.73 | KDM1A (0.41) | TDO2CYP1A2CYP3A4NPY5RALDH1A1 | |
| SCHEMBL4224624 | 0.72 | AQP1 (0.55) | CYP17A1TDO2CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL27703115 | 0.70 | MAPT (0.39) | GPR84 | |
| SCHEMBL27723658 | 0.70 | TAAR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101448492-A | Methods of treating cognitive and other disorders | WYETH CORP (US) | 2009-06-03 | — | — | CN | claimed |
| CN-101389325-A | Treatment of drug abuse | WYETH CORP (US) | 2009-03-18 | — | — | CN | claimed |
| CN-101203217-A | Methods for modulating bladder function | WYETH CORP (US) | 2008-06-18 | — | — | CN | claimed |
| CN-101198323-A | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH CORP (US) | 2008-06-11 | — | — | CN | claimed |
| CN-101198322-A | Novel therapeutic combinations for the treatment or prevention of depression | WYETH CORP (US) | 2008-06-11 | — | — | CN | claimed |
| CN-101189004-A | Treatment of pain | WYETH CORP (US) | 2008-05-28 | — | — | CN | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| CN-101448492-A | Methods of treating cognitive and other disorders | WYETH CORP (US) | 2009-06-03 | — | — | CN | disclosed |
| CN-101389325-A | Treatment of drug abuse | WYETH CORP (US) | 2009-03-18 | — | — | CN | disclosed |
| CN-101203217-A | Methods for modulating bladder function | WYETH CORP (US) | 2008-06-18 | — | — | CN | disclosed |
| CN-101198323-A | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH CORP (US) | 2008-06-11 | — | — | CN | disclosed |
| CN-101198322-A | Novel therapeutic combinations for the treatment or prevention of depression | WYETH CORP (US) | 2008-06-11 | — | — | CN | disclosed |
| CN-101189004-A | Treatment of pain | WYETH CORP (US) | 2008-05-28 | — | — | CN | disclosed |